Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Xencor Inc revenues decreased 54% to $29.8M. Net loss increased 62% to $134M. Revenues reflect Royalties segment decrease from $27.1M to $0K, Research collaboration segment decrease from $22.4M to $0K. Higher net loss reflects Impairment on equity securities increase from $0K to $20.4M (expense), (Loss) gain on equity securities, net - increase from $2.5M to $7.4M (expense).